Updates are available Correction dated 2026-04-02
Click to view Correction: https://doi.org/10.1038/s41591-026-04379-6
-
Authors
van Putten, Jeffrey
Snaebjornsson, Petur https://orcid.org/0000-0002-1086-8108
Bosch, Linda J. W.
Koster, Roelof https://orcid.org/0000-0003-1424-8579
Roepman, Paul
Usset, Joseph
Boelens, Mirjam C.
van Wezel, Tom
Rosenberg, Efraim H. https://orcid.org/0000-0002-3859-6941
Marchetti, Serena
Vollebergh, Marieke
Lambregts, Doenja M. J.
van der Kolk, Lizet E.
Cuppen, Edwin https://orcid.org/0000-0002-0400-9542
Nienhuis, Hilde H.
Monkhorst, Kim https://orcid.org/0000-0002-8690-3811
- License Information
-
More Information
Article History
Received: 10 February 2025
Accepted: 10 February 2026
First Online: 20 March 2026
Change Date: 2 April 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-026-04379-6
Competing interests
: E.C. reports consultancy fees and support for attending meetings and traveling from Illumina, Ultima Genomics and Roche. H.H.N. reports consultancy fees from Bayer, Roche, J&J, Illumina, AstraZeneca, Amgen and Eli Lilly. The other authors declare no competing interests.
